Homocysteine (HCY), a redox-active metabolite of the methionine cycle, is of particular clinical interest because of its association with various neurodegenerative diseases including amyotrophic lateral sclerosis. It has been previously established that HCY exacerbates damage to motor neurons from reactive oxygen species (ROS) such as hydrogen peroxide. To assess the role of HCY at the mammalian neuromuscular junction, neurotransmission was monitored by electrophysiology at the mouse epitrochleoanconeus muscle. Preparations were preincubated in HCY before inducing ROS and recordings were taken before and after ROS treatment. In this study, HCY was observed to sensitize the neuromuscular junction to ROS-induced depression of spontaneous transmission frequency, an effect we found to be mediated by a N-methyl-D-aspartate receptor (NMDAR) and nitric oxide (NO). The NMDAR antagonist D, L-2-amino-5-phosphonopentanoic acid prevented the HCY-induced sensitization to oxidative stress. Disrupting NO activity with either the nitric oxide synthase I antagonist Nω-nitro-L-arginine methyl ester hydrochloride or the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide potassium salt also prevented sensitization.
Introduction
Homocysteine (HCY), a metabolic intermediate of the methionine cycle, is also a redox-active neurotoxin that markedly reduces cell viability [1, 2] . It is of particular biological interest as elevated levels of HCY have been observed in the blood plasma of patients diagnosed with amyotrophic lateral sclerosis (ALS) [3] , a neurodegenerative disease characterized by the progressive deterioration of neuromuscular junctions (NMJ) contributing to muscle weakness and paralysis [4] . Its specific mechanism of action remains yet to be fully characterized, but an association has been found linking HCY to the promotion of free radicals and accumulation of cytosolic calcium [3, 5] . The balance of free radicals at the NMJ is of particular importance as they can cause motor deficits by synaptic pruning of existing synapses [6] . Recently, HCY has been shown to impair motor neurons by sensitizing the NMJ to oxidative stress, a general term that refers to the damage and disruption of cellular machinery due to an imbalance of oxidant and antioxidant levels [7] . This only further confirms it as a risk factor for ALS [8] and has prompted interest in a more indepth examination of HCY's mechanism of action at the NMJ.
Historically, the NMJ has been characterized as an exclusively cholinergic synapse [9] , but more recent findings suggest that the neurotransmitter glutamate functions at the NMJ [10] [11] [12] . Several types of glutamate receptors, including the N-methyl-D-aspartate receptor (NMDAR), have been identified at the NMJ [11, 13] . As HCY is known to activate the GluN2A subunit of NMDARs [5] , this would provide a possible path through which HCY might damage motor neurons. Hyperactivity of NMDARs is concerning as it has been linked to heightened calcium influx resulting in ROS generation and elevated levels of oxidative stress [14] . Subsequent studies have showed a close association between NMDARs and nitric oxide synthase (NOS) I [15, 16] , suggesting a potential involvement of nitric oxide (NO) in the effects of activating NMDARs at the NMJ, providing another line of investigation into HCY's potential mechanism of action. Characterization of this pathway may provide further insight into treatment for ALS as it will illuminate the pathological implications of the elevated levels of HCY found in the blood plasma of ALS patients [3] . In this report, we describe a bifurcated mechanism of HCY at the NMJ wherein it (i) aggravates reactive oxygen species (ROS)-induced depression of neurotransmitter release frequency by an NMDAR-NOS-I complex and (ii) depresses quantal content independently of NOS-I or ROS.
Materials and methods
Experimental preparation and solutions C57BL/6 mice (aged 6-8 weeks; Jackson Laboratories, Bar Harbor, Maine, USA) were anesthetized using a CO 2 induction chamber. The mouse epitrochleoanconeus (ETA) muscle and its associated nerve were extracted as described in Bradley et al. [17] In all of our experiments, drugs were administered through a perfusion bath of mouse ringer solution. All drugs were stored at − 20°C at a stock concentration until the day of the experiment when the stock was diluted to the appropriate concentration for each respective experiment. In all experiments, µ-Conotoxin GIIIB (Alomone Labs, Jerusalem, Israel) was applied to the preparation 30 min before electrophysiology to inhibit action potentials in the muscle. For all experiments that required HCY incubation, 500 µM D,L-HCY (Sigma-Aldrich, St. Louis, Missouri, USA) was administered for 3 h before electrophysiological recordings and sustained throughout the entire experiment. To induce acute oxidative stress from reactive oxygen species, 300 µM H 2 O 2 was administered for 30 min before recording as per previously documented methodology wherein a 300 µM H 2 O 2 dosage was sufficient to induce acute depression of evoked end-plate potential amplitudes [8, 18] . All other drugs were administered for the duration of their respective experiments. In Fig. 1 , a concentration of 50 µM D,L-2-amino-5-phosphonopentanoic acid (AP-5; Sigma-Aldrich), 300 µM Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME; Sigma-Aldrich), 40 µM 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide potassium salt (CPTIO; Sigma-Aldrich), and 100 µM diethylamine NONOate diethylammonium (DEANO; Sigma-Aldrich) with 100 µM L-NAME were administered.
Electrophysiology
End-plate potentials were evoked by stimulating the ETA muscle motor nerve axon with single depolarizing square pulses using a SD-9 Stimulator (Grass Instrument Co., Quincy, Massachusetts, USA) set at a frequency of 0.2 Hz, duration of 0.2 ms, and a suprathreshold voltage to induce an action potential in the motor nerve by a suction electrode. End-plate potentials were recorded using glass microelectrodes (3 M KCl; resistance: 5-20 MΩ) prepared from 1.2-mm borosilicate glass capillaries with filament (World Precision Instruments, Sarasota, Florida, USA). Membrane potentials were amplified using an A-M Systems Model 1600 Amplifier (A-M Systems, Sequim, Washington, USA) and recorded with AD-Instruments PowerLab 4/25 paired with its associated LabChart software (AD-Instruments, Colorado Springs, Colorado, USA). Recordings were taken in randomly selected ETA muscle fibers and the microelectrode was inserted into each cell for roughly 100 s, collecting a minimum of at least 20 end-plate potentials and 50 miniature end-plate potentials (mEPPs).
Immunofluorescence ETA muscles were fixed in 4% paraformaldehyde for 15 min at room temperature. After rinsing, they were permeabilized with 0.3% Triton X-100 for 30 min at 37°C, and then rinsed for 1 h (3 × 20 min) in Blocking Solution (BS; 0.01% Triton X-100, 1% BSA) to reduce nonspecific staining. Polyclonal rabbit anti-NMDAR2A IgG (A-6473; Thermo Fisher Scientific, Waltham, Massachusetts, USA) was applied at 1 : 200 dilution in BS overnight at 4°C. Goat anti-rabbit IgG conjugated to Alexa Fluor 555 (Thermo Fisher Scientific) was then applied at 1 : 500 dilution for 3 h at 37°C and washed in BS. α-Bungarotoxin conjugated to Alexa Fluor 488 (Thermo Fisher Scientific) was applied at 1 : 200 for 15 min to label the nicotinic acetylcholine (ACh) receptors. After further rinsing, the muscles were mounted on microscope slides in Slow Fade Diamond Antifade Mountant (Thermo Fisher Scientific).
Muscles were imaged using an IX81 inverted microscope (Olympus Microscope Co., Waltham, Massachusetts, USA) with a spinning-disk confocal attachment and Orca EM camera (Hamamatsu, Japan). A standard FITC filter set (Ex: 470/90 nm; DM: 495 nm; Em: 525/50 nm, Chroma Technology Corp., Bellows Falls, Vermont, USA) and a TRITC filter set (Ex: 545/30 nm; DM: 570 nm; Em: 620/60 nm, Chroma Technology Corp., Bellows Falls, Vermont, USA) were used to image the fluorophores. All images were acquired, adjusted for optimal brightness, and analyzed with SlideBook 6 software (3i; Intelligent Imaging Innovations, Denver, Colorado, USA).
Data analysis
All data are presented as mean SE. Statistical significance was assessed using Student's paired t-test for measurements taken before and after H 2 O 2 treatment on the same preparation. For measurements across different preparations, Student's two-sample t-test was used.
Results

HCY sensitizes the NMJ to ROS-induced depression of transmitter release
Our first endeavor was to confirm the previous findings of Bukharaeva et al. [8] , which showed that HCY sensitizes the NMJ to oxidative stress. mEPP frequencies were used to quantify spontaneous release of ACh from the nerve terminal and serve as a measure of neurotransmitter release. In our control experiments, mEPP frequencies were initially measured at 4.29 0.44 Hz (mean SE). Application of H 2 O 2 to induce mild oxidative stress caused an insignificant change to 4.37 0.74 Hz (Fig. 1) . It was only when the ETA muscle was incubated in D, L HCY for 3 h before exposure to H 2 O 2 that a significant 31% decrease in mEPP frequency from 3.65 0.39 to 2.23 0.24 Hz was observed (Fig. 1) , thus supporting Bukharaeva et al. [8] . For ease of reference in future comparison, we will refer to back to this significant 31% decrease in mEPP frequency from HCY-induced sensitization of the NMJ to oxidative stress as the standard HCY-H 2 O 2 effect.
HCY-H 2 O 2 -induced depression of transmitter release is mediated by NMDARs and nitric oxide
There is pharmcological evidence that HCY activates the GluN2A subunit of NMDARs [5] . To explore whether this mediates HCY's effects at the mouse NMJ as proposed by Bukharaeva et al. [8] , we first confirmed the presence of NMDARs using immunofluorescence.
Application of an NMDAR2A antibody shows specific staining at the NMJ (Fig. 2a) . Co-staining with α-bungarotoxin (Fig. 2b) , which labels nicotinic ACh receptors, confirmed the presence of NMDARs at the NMJ (Fig. 2c) ; however, it was not possible to localize these receptors to any specific component of the NMJ (e.g. the nerve terminal, muscle, or Schwann cell).
After ascertaining that NMDARs are present, we applied the NMDAR antagonist AP-5. As seen in Fig. 1 After confirming the role of NMDARs in HCY-induced sensitization to oxidative stress, we sought to characterize the next target in the pathway. Since previous work has shown that NOS-I co-localizes with NMDARs at the NMJ [15, 16] , we posited that the HCY pathway utilizes NO. Therefore, we applied the nitric oxide synthase antagonist L-NAME to disrupt the pathway and see whether this blocked the effect of HCY. As seen in Fig. 1 , application of L-NAME successfully blocked the HCY-induced depression of mEPP frequency. With L-NAME, an insignificant 14% decrease from 5.51 0.81 to 4.58 0.58 Hz was observed upon application of H 2 O 2 as compared with the significant 31% decrease observed from the standard HCY-H 2 O 2 effect. To determine whether NO must pass through the extracellular space to reach its target, we applied the membrane-impermeable NO scavenger CPTIO. Application of CPTIO blocked the standard HCY-H 2 O 2 effect as only an insignificant 7% decrease from 3.66 0.55 to 3.35 0.52 Hz in mEPP frequency was observed (Fig. 1) . Having shown that disrupting either NO production or its diffusion through the extracellular space blocks the depression of mEPP frequencies from HCYinduced sensitization of the NMJ to oxidative stress, the next step was to determine whether it was possible to reconstitute the standard HCY-H 2 O 2 effect by replacing HCY with an exogenous NO donor.
HCY treatment was replaced with exposure to the exogenous NO donor DEANO. DEANO successfully reconstituted the standard HCY-H 2 O 2 effect in the absence of HCY. A significant 62% decrease in mEPP frequency from 2.02 0.26 to 0.744 0.07 Hz was observed upon treatment with DEANO that was even more potent than the standard HCY-H 2 O 2 effect of a 31% decrease (Fig. 1) .
HCY can independently depresses quantal content at the NMJ
In addition to sensitizing the NMJ to oxidative stress, HCY also independently decreased evoked neurotransmitter release. As seen in Fig. 3a , HCY treatment alone causes a significant decrease in quantal content from 75.14 6.39 to 54.02 3.69. Moreover, treatment with the NMDAR antagonist AP-5 blocks this effect and restores quantal content levels to 77.53 3.31. Surprisingly, NO does not seem to be involved in this effect of HCY. Inhibiting NOS with L-NAME did not block the HCY effect, as a decrease in quantal content to 54.60 4.11 was still observed. Applying an exogenous donor of NO also had no effect as a decrease in quantal content to 54.61 2.31 was observed once again (Fig. 3) . Therefore, HCY can independently induce a depression of quantal content, an effect that is mediated through NMDARs with a mechanism unrelated to NO. A closer examination of the electrophysiological traces revealed that HCY increases mEPP amplitudes while having no significant effect on EPP amplitudes, thus resulting in the overall decrease of quantal content (Fig. 3b and c) .
Discussion
HCY sensitizes the NMJ to the effects of oxidative stress by nitric oxide
We carried out this investigation because recent research had shown that HCY aggravates the negative effects of ROS on neurotransmitter release at the mouse NMJ [8] .
As shown in Fig. 1 , preincubation of the mouse ETA muscle in HCY aggravated decreases in mEPP frequency upon exposure to oxidative stress, thus confirming the results of Bukharaeva et al. [8] . Since previous work has shown HCY activates the GluN2A subunit of NMDA receptors [5] , we expected that HCY's mechanism of action at the mouse NMJ would be mediated through NMDARs. After demonstrating the presence of NMDARs at the NMJ (Fig. 2) , we showed that the application of an NMDAR antagonist successfully blocked the HCY-H 2 O 2 -induced depression of mEPP frequency (Fig. 1) , thus providing anatomical evidence and further confirming the pharmacological evidence by Bukharaeva et al. [8] for the involvement of NMDARs.
To our knowledge, this paper provides the first pharmacological evidence for the next target in this pathway. Although it has been previously shown that NOS-I colocalizes with the NMDAR subunit 1 at the mouse NMJ [15] , this is the first description of a NMDAR-NOS-I complex mediating HCY-induced sensitization of the NMJ to oxidative stress. We have clear pharmacological evidence that inhibiting either NO synthesis or its diffusion through the extracellular space blocks the characteristic depression of mEPP frequency (i.e. the HCY-H 2 O 2 effect; Fig. 1 ). As the target of NO is typically the presynaptic nerve terminal, we speculate that the source of NO is either the muscle or the perisynaptic Schwann cell.
The involvement of NO is particularly relevant because there is a strong evidence that nitric oxide is involved in modulating the release of ACh at the rat NMJ [16, 19] and multiple studies have specifically linked NO activity to inhibiting release of ACh in amphibian and mammalian synapses [20, 21] . We propose that the HCY-induced nitric oxide diffuses from the postsynaptic cell to the presynaptic cell where nitric oxide then undergoes a favorable reaction with a ROS to generate peroxynitrite [22] . Interestingly, peroxynitrite has been directly linked to the impairment of SNAP-25, a synaptic release protein whose activity facilitates synaptic transmission [22, 23] . This model we are proposing explains why synaptic transmission is reduced only during the coincidence of HCY and ROS, as the formation of peroxynitrite is dependent on the presence of both.
HCY reduces quantal content at the mouse NMJ
We also observed a novel secondary effect of HCY where incubation in HCY alone was sufficient to significantly decrease quantal content at the mouse NMJ even in the absence of ROS. This effect is mediated by NMDARs as an application of an antagonist effectively abolishes the depression in quantal content. Yet, it is clearly a distinct pathway from the standard HCY-H 2 O 2 effect as interference with NO production and activity did not block the effect. This complicates the mechanism of HCY action at the NMJ as it suggests that HCY acts through a bifurcated pathway.
As HCY-induced depression of quantal content is mediated by NMDARs, but not NOS, we propose that the NMDA-induced calcium influx is targeting something entirely different than NOS to inhibit evoked release of ACh. Instead, it likely triggers a calciumdependent cascade that may involve CaMKII, a kinase that increases cholinergic receptor density on the postsynaptic cell [24] , a possibility that is consistent with our electrophysiological results detailing HCY-induced increases in mEPP amplitudes. It is known that there are various synaptic homeostatic mechanisms that involve retrograde signaling that can modulate presynaptic activity on the basis of the state of the postsynaptic cell [25] . Therefore, we propose that the synapse adapts to this increase in postsynaptic receptor density in the postsynaptic cell by releasing fewer quanta of ACh from the presynaptic cell.
Accounting for HCY's bifurcated mechanism of action at the NMJ, we propose a two-factor model where HCY lowers neurotransmission at the NMJ through (i) an indirect effect wherein HCY aggravates the effects of oxidative stress by an NMDAR-NOS-I complex and (ii) a direct effect where HCY induces a calcium-dependent cascade modifying synaptic machinery. A better understanding of HCY's role at the NMJ is critical to developing therapies for ALS as many potential treatments focus on degrading or inhibiting HCY activity at the NMJ [3] , a task that requires recognition of HCY's multifaceted effects.
Conclusion
Our data show that HCY acts synergistically with ROS to induce significant decreases in neurotransmission at the NMJ through a mechanism mediated by NO. Before this study, there were only hypothetical models for the mediator between NMDAR activation from HCY and its induced pathologies. To our knowledge, this study provides the first pharmacological data implicating NO's involvement in HCY sensitizing the NMJ to ROSinduced decrease of neurotransmission. Interestingly, HCY was observed to also decrease quantal content in a separate mechanism mediated by NMDARs independent of both NO and ROS. These results show a more complicated mechanism of action than previously hypothesized where HCY acts in a bifurcated pathway at the Homocysteine induces quantal content depression through N-methyl-D-aspartate receptors (NMDARs) independent of nitric oxide (a) Quantal contents were calculated from the ratio of end-plate potential (EPP) amplitude to miniature end-plate potentials (mEPP) amplitude. Each data point represents the mean quantal content calculated from each condition (1) control: 50 synapses across 10 mice (2) Homocysteine (HCY): 75 synapses across 15 mice (3) Homocysteine + AP-5: 35 synapses across seven mice (4) homocysteine + L-NAME: 30 synapses across six mice (5) homocysteine + DEANO + L-NAME: 25 synapses across five mice. Data were analyzed using Student's t-test (significant differences from control of P < 0.05 were found in the HCY, HCY + L-NAME, and HCY + DEANO + L-NAME conditions) (b) Representative electrophysiological traces of an EPP measured under control conditions versus HCY treatment (c) Distribution of mEPP frequencies comparing control conditions (n = 272 traces) versus HCY treatment (n = 296 traces). AP-5, D,L-2-Amino-5-phosphonopentanoic acid; DEANO, diethylamine NONOate diethylammonium; L-NAME, Nω-nitro-L-arginine methyl ester hydrochloride.
NMJ to reduce neurotransmission via two independent mechanisms.
